This trial is randomized, double-blinded study to evaluate the safety, efficacy and immunogenicity of ABP 798 compared with Rituximab in patients with CD20 Positive B-Cell Non-Hodgkin Lymphoma
- Conditions
- Health Condition 1: C823- Follicular lymphoma grade IIIa
- Registration Number
- CTRI/2017/12/010935
- Lead Sponsor
- Amgen Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 257
1.Histologically confirmed (by lymph node or extranodal region biopsy), Grade 1, 2, or 3a follicular B-cell NHL expressing CD20 within 12 months before randomization
2. Stage 2, 3, or 4 (per Cotswoldâ??s Modification of Ann Arbor Staging System
3. Low tumor burden based on the GELF Criteria
a.largest nodal or extranodal mass <= 7 cm
b. no more than 3 nodal sites with diameter > 3 cm
c.no splenomegaly > 16 cm by CT scan and no symptomatic splenomegaly
d. no significant pleural or peritoneal serous effusions by CT
e.lactate dehydrogenase <= upper limit of normal (ULN)m before any study specific procedures
f. no B symptoms (night sweats, fever [temperature > 38°C], weight loss > 10% in the previous 6 months)
4. Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 with measurable disease (per International Working Group)
a. subjects must have a baseline scan (computed tomography [CT]) of the neck (if palpable lymph node > 1.0 cm), chest, abdomen, and pelvis to assess disease burden within 6 weeks before randomization
b. subjects must have had a baseline bone marrow biopsy within 12 months before randomization. Previously confirmed positive bone marrow involvement does not need to be repeated for purposes of screening.
5. Blood counts:
a.absolute neutrophil count (ANC) >= 1.5 x 109/L (1,500/μL)
b. lymphocytes < 1.5 x the ULN
c.platelets >= 100 x 109/L (100,000/μL)
d. hemoglobin >= 10.0 g/dL
6. Adequate hepatic function as defined by:
a.total bilirubin < 1.5 x the ULN
b. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 x ULN
c. Subjects with an elevated unconjugated bilirubin will be eligible if hepatic enzymes and function are otherwise within normal limits and there is no evidence of hemolysis.
7. Adequate renal function as defined by creatinine < 1.5 x ULN or estimated creatinine clearance >= 50 mL/min calculated by the Cockcroft-Gault method
8. Subjects must sign an IRB-approved informed consent form before any study specific procedures.
1.Diffuse large cell component and/or Grade 3b follicular NHL
2. History or known presence of central nervous system metastases
3. Palliative radiotherapy within 3 months before randomization
4. Malignancy other than NHL within 5 years (except treated in-situ cervical cancer, or
squamous or basal cell carcinoma of the skin)
5. Major surgical procedure within 4 weeks before randomization or planned major surgical
procedure during the treatment phase
6. Any of the following in the 6 months before randomization:
• clinically significant cardiovascular disease (including myocardial infarction, unstable
angina, symptomatic congestive heart failure [New York Heart Association
>= Class III], serious uncontrolled cardiac arrhythmia); peripheral vascular disease,
cerebrovascular accident, or transient ischemic attack
7. Medically uncontrolled hypertension or systolic blood pressure > 160 mmHg or diastolic
blood pressure > 100 mmHg
8. Known active or history of active tuberculosis (TB)
9. Positive for hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C virus
antibody at screening
10. Known to be human immunodeficiency virus positive
11. Recent infection requiring a course of systemic anti-infective agents that was completed
<= 7 days before randomization (with the exception of uncomplicated urinary tract
infection)
12. Other investigational procedures that can impact the study data, results, or patient
safety while participating in this study are excluded; participation in observational
studies is allowed.
13. Subject is currently enrolled in or has not yet completed at least 30 days or 5 half-lives
(whichever is longer) since ending other investigational device or drug study(s), including
vaccines, or subject is receiving other investigational agent(s)
14. Previous use of either commercially available or investigational chemotherapy, biological,
or immunological therapy for NHL (including rituximab or biosimilar rituximab, or other
anti-CD20 treatments)
15. Systemic corticosteroid use within 3 months before randomization (inhaled are
allowable)
16. Live vaccines within 28 days prior to the first dose of IP
17. History of neurologic symptoms suggestive of central nervous system demyelinating
Disease
18. Woman of childbearing potential who is pregnant or is breastfeeding
19. Woman of childbearing potential who does not consent to use highly effective methods of
birth control (eg, true abstinence, sterilization, birth control pills, Depo Provera injections,
or contraceptive implants) during treatment and for an additional 12 months after the last
administration of the protocol specified-treatment
20. Man with a partner of childbearing potential who does not consent to use highly effective
methods of birth control (eg, true abstinence, vasectomy, or a condom in combination
with hormonal birth control or barrier methods used by the woman) during treatment and
for an additional 12 months after the last administration of the protocol specified
treatment
21. Subject has known sensitivity to any of the products to be administered during the study,
including mammalian cell derived drug products
22. Subject p
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Risk difference (RD) of overall response rate (ORR) of efficacy of ABP 798 compared with rituximab.Timepoint: week 28
- Secondary Outcome Measures
Name Time Method Geometric mean ratio (GMR) of test (ABP 798)-to-reference (rituximab)Timepoint: Predose and after end of infusion at week 12;Incidence of anti-drug antibodiesTimepoint: Up to Week 28;On study overall survivalTimepoint: Up to Week 28;On study progression-free survivalTimepoint: Up to Week 28;Percent of subjects with complete depletion of CD19 cell count and total Immunoglobin G (IgG) and IgM antibody levelsTimepoint: Baseline to study day 8;Risk difference (RD) of overall response rate (ORR)of efficacy of ABP 798 compared with rituximab.Timepoint: Week 12;Serum concentrations at predose and immediately after the end of infusionTimepoint: week 12;Subject incidence of treatment-emergent AEs and serious adverse events. Clinical significant changes in laboratory values and vital signs will be reported as AEsTimepoint: Up to Week 28